Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.24 - $8.75
Previous CloseN/A
Volume228.85K
Average Volume (3M)1.59M
Market Cap
$99.11M
Enterprise Value$67.77M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Mar 19, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding33,311,543
10 Day Avg. Volume3,395,053
30 Day Avg. Volume1,594,051
Standard Deviation0.30
R-Squared0.00071
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-82.44
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$10.33Price Target Upside497.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Rani Therapeutics Holdings News
PremiumCompany Announcements
Rani Therapeutics Advances in Biotherapeutics Market
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRani reported its financial results, recording a net loss of $0.44 per share, which was better than the prior estimate of a net loss of $0.55 per share.
Market PotentialThe obesity market is massive, and Rani seems to be positioning itself to serve different segments with its drug profiles, offering opportunities in this segment.
Partnership And CollaborationRani Therapeutics announced an agreement with ProGen to develop a GLP-1/GLP-2 dual agonist using RaniPill, offering a potential new contender in obesity treatment.
Bears Say
Clinical RisksRisks include negative Phase 2 data, negative clinical readouts with other candidates, and failure to achieve approvals for key pipeline projects.
Market UptakeThere is a risk of slower-than-projected market uptake for Rani's products.
Partnership RisksPossible partnership risk could impact the development and economic benefits of the RaniPill technology.
---
Options Prices
Currently, No data available
---
Ownership Overview
29.74% Insiders
2.80% Mutual Funds
5.81% Other Institutional Investors
59.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Rani Therapeutics Holdings
Desktop Users
Mobile Users
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $1.24 and its highest was $8.75 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Rani Therapeutics Holdings’s market cap is $99.11M.
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is Mar 19, 2025 which is in 25 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Rani Therapeutics Holdings released its earnings results on Nov 14, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.05.
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate is -0.27.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 33,311,543 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Rani Therapeutics Holdings reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -4.858%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
---
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (497.11% Upside)
$10.33 (497.11% Upside)
Insider Transactions
Bought Shares
Worth $50.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.25%
12-Months-Change
Fundamentals
Return on Equity
-272.52%
Trailing 12-Months
Asset Growth
-38.19%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
---
RANI Stock 12 Month Forecast
Average Price Target
$10.33
▲(497.11% Upside)
Technical Analysis
Verastem
―
Arcturus Therapeutics
―
Oramed Pharm
―
XTL Biopharmaceuticals Ltd. Sponsored ADR
―
PAVmed
―
Best Analysts Covering RANI
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-28.29%
reiterated a buy rating 18 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -28.29% per trade.
---